Author:
Guan Xiuwen,Ma Fei,Sun Xiaoying,Li Chunxiao,Li Lixi,Liang Fang,Li Shaochuan,Yi Zongbi,Liu Binliang,Xu Binghe
Reference47 articles.
1. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer;Blum;J Clin Oncol.,1999
2. NCCN, Guidelines: Breast Cancer, Version, 2,.2019
3. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer;Oshaughnessy;Ann Oncol.,2001
4. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer;Fumoleau;Eur J Cancer.,2004
5. Adjuvant capecitabine for breast cancer after preoperative chemotherapy;Masuda;N Engl J Med.,2017
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献